Synapse - Imane El Dika

Results (67)

Maximizing response: A case report of salvage chemotherapy after immune checkpoint inhibition in a patient with previous chemo-refractory metastatic esophageal carcinoma

Journal Article

Greally, M.; Agarwal, R.; El Dika, I.; Shamseddine, A.; El-Olayan, A.; Haibe, Y.; Paroder, V.; Shia, J.; Abou-Alfa, G. K.; Ku, G. Y.
Journal of Gastrointestinal Oncology (2019)

Fulltext@MSK | Save

Prospective genotyping of hepatocellular carcinoma: Clinical implications of next-generation sequencing for matching patients to targeted and immune therapies

Journal Article

Harding, J. J.; Nandakumar, S.; Armenia, J.; Khalil, D. N.; Albano, M.; Ly, M.; Shia, J.; Hechtman, J. F.; Kundra, R.; El Dika, I.; more...
Clinical Cancer Research (2019)

Fulltext@MSK | Save

A phase Ib, open-label study of dalantercept, an activin receptor-like kinase 1 ligand trap, plus sorafenib in advanced hepatocellular carcinoma

Journal Article

Abou-Alfa, G. K.; Miksad, R. A.; Tejani, M. A.; Williamson, S.; Gutierrez, M. E.; Olowokure, O. O.; Sharma, M. R.; El Dika, I.; Sherman, M. L.; Pandya, S. S.
The Oncologist (2019)

Fulltext@MSK | Save

Binimetinib plus gemcitabine and cisplatin phase I/II trial in patients with advanced biliary cancers

Journal Article

Lowery, M. A.; Bradley, M.; Chou, J. F.; Capanu, M.; Gerst, S.; Harding, J. J.; El Dika, I.; Berger, M.; Zehir, A.; Ptashkin, R.; more...
Clinical Cancer Research (2019)

Fulltext@MSK | Save

Phase II trial of sorafenib plus doxorubicin (SD) in patients (Pts) with advanced hepatocellular carcinoma (HCC) after progression of disease (PD) on sorafenib (S)

Meeting Abstract

El Dika, I. H.; Capanu, M.; Chou, J. F.; Harding, J. J.; Hrabovsky, A. D.; Do, R. K. G.; Shia, J.; Germino, J.; O'Reilly, E. M.; Abou-Alfa, G. K.
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB80802 (Alliance) (C8)